Published online September 1, 2008
PEDIATRICS Vol. 122 No. 3 September 2008, pp. e771-e777 (doi:10.1542/peds.2008-1002)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wood, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wood, R. A.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Arboviruses (also see West Nile...
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SPECIAL ARTICLE

An Algorithm for Treatment of Patients With Hypersensitivity Reactions After Vaccines

Robert A. Wood, MDa, Melvin Berger, MD, PhDb, Stephen C. Dreskin, MD, PhDc, Rosanna Setse, MD, MPHd, Renata J.M. Engler, MDe, Cornelia L. Dekker, MDf, Neal A. Halsey, MDa,d the Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network

a Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
b Departments of Pediatrics and Medicine, University Hospitals of Cleveland, Cleveland, Ohio
c Division of Allergy and Immunology, University of Colorado Health Sciences Center, Denver, Colorado
d Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland
e Vaccine Healthcare Center Network, Walter Reed Army Medical Center, Washington, DC
f Division of Pediatric Infectious Diseases, Stanford University School of Medicine, Stanford, California

Concerns about possible allergic reactions to immunizations are raised frequently by both patients/parents and primary care providers. Estimates of true allergic, or immediate hypersensitivity, reactions to routine vaccines range from 1 per 50000 doses for diphtheria-tetanus-pertussis to ~1 per 500000 to 1000000 doses for most other vaccines. In a large study from New Zealand, data were collected during a 5-year period on 15 marketed vaccines and revealed an estimated rate of 1 immediate hypersensitivity reaction per 450000 doses of vaccine administered. Another large study, conducted within the Vaccine Safety Datalink, described a range of reaction rates to >7.5 million doses. Depending on the study design and the time after the immunization event, reaction rates varied from 0.65 cases per million doses to 1.53 cases per million doses when additional allergy codes were included. For some vaccines, particularly when allergens such as gelatin are part of the formulation (eg, Japanese encephalitis), higher rates of serious allergic reactions may occur. Although these per-dose estimates suggest that true hypersensitivity reactions are quite rare, the large number of doses that are administered, especially for the commonly used vaccines, makes this a relatively common clinical problem. In this review, we present background information on vaccine hypersensitivity, followed by a detailed algorithm that provides a rational and organized approach for the evaluation and treatment of patients with suspected hypersensitivity. We then include 3 cases of suspected allergic reactions to vaccines that have been referred to the Clinical Immunization Safety Assessment network to demonstrate the practical application of the algorithm.


Key Words: immunization • vaccines • hypersensitivity

Abbreviations: MMR—measles-mumps-rubella • DTaP—diphtheria-tetanus-acellular pertussis • IgE—immunoglobulin E • HiB—Haemophilus influenzae type B • Tdap—tetanus-diphtheria-pertussis • MCV—meningococcal conjugate vaccines


Accepted May 21, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BMJHome page
P. B McIntyre, J. M L Brotherton, M. A Burgess, and A. S Kemp
More data from Australia on sensitivity to HPV vaccine
BMJ, January 9, 2009; 338(jan09_1): b26 - b26.
[Full Text]